Genzyme Corporation, a global leader in biotechnology, and the International Center for Genetic Engineering and Biotechnology (ICGEB), a not-for-profit research and development (R&D) organization, announced today a new research collaboration to advance treatments for neglected diseases.  More›

Genzyme Corporation today announced that the FDA plans an Accelerated Approval for Myozyme® (alglucosidase alfa) produced at the 2000 L bioreactor scale for the treatment of Late Onset Pompe disease. More›

Genzyme and Osiris Therapeutics announced today that they have entered a strategic alliance for the development and commercialization of Prochymal and Chondrogen, two novel, late-stage adult stem cell treatments that hold significant potential to treat a wide range of diseases.  More›